JavaScript NENÍ povolen !

Článek

FT
Medvik - BMČ

Je něco špatně v tomto záznamu ?

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

R. Hájek, T. Masszi, MT. Petrucci, A. Palumbo, L. Rosiñol, A. Nagler, KL. Yong, A. Oriol, J. Minarik, L. Pour, MA. Dimopoulos, V. Maisnar, D. Rossi, H. Kasparu, J. Van Droogenbroeck, DB. Yehuda, I. Hardan, M. Jenner, M. Calbecka, M. Dávid, J. de...

Leukemia. 2017 ; 31 (1) : 107-114. [pub] 20160624

ISSN 1476-5551
Medvik
Zdroj

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz https://www.medvik.cz/link/bmc17031586

Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Nursing & Allied Health Database (ProQuest) od 2000-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Public Health Database (ProQuest) od 2000-01-01 do Před 1 rokem

PubMed 27416912
DOI 10.1038/leu.2016.176
Knihovny.cz E-zdroje

This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma patients were randomized (1:1) to receive carfilzomib (10-min intravenous infusion; 20 mg/m(2) on days 1 and 2 of cycle 1; 27 mg/m(2) thereafter) or a control regimen of low-dose corticosteroids (84 mg of dexamethasone or equivalent corticosteroid) with optional cyclophosphamide (1400 mg) for 28-day cycles. The primary endpoint was overall survival (OS). Three-hundred and fifteen patients were randomized to carfilzomib (n=157) or control (n=158). Both groups had a median of five prior regimens. In the control group, 95% of patients received cyclophosphamide. Median OS was 10.2 (95% confidence interval (CI) 8.4-14.4) vs 10.0 months (95% CI 7.7-12.0) with carfilzomib vs control (hazard ratio=0.975; 95% CI 0.760-1.249; P=0.4172). Progression-free survival was similar between groups; overall response rate was higher with carfilzomib (19.1 vs 11.4%). The most common grade ⩾3 adverse events were anemia (25.5 vs 30.7%), thrombocytopenia (24.2 vs 22.2%) and neutropenia (7.6 vs 12.4%) with carfilzomib vs control. Median OS for single-agent carfilzomib was similar to that for an active doublet control regimen in heavily pretreated RRMM patients.

Amedeo Avogadro University of Eastern Piedmont Novara Italy

AZ Sint Jan Brugge Belgium

Center for Oncology Hematology with Outpatient Department and Palliative Care Wilhelminenspital Vienna Austria

Chaim Sheba Medical Center Tel Hashomer Israel

Charles University Teaching Hospital Hradec Králové Czech Republic

Clinica di Ematologia Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona Ancona Italy

Clínica Universidad de Navarra CIMA IDISNA Navarra Spain

Hadassah Medical Center Jerusalem Israel

Hopital Huriez CHRU Lille France

Hospital Clínic de Barcelona Barcelona Spain

Hospital Elisabethinen Linz Linz Austria

Institut Català d'Oncologia Hospital Germans Trias i Pujol Barcelona Spain

Medical University of Vienna Vienna Austria

Meir Medical Center Kfar Saba Israel

National and Kapodistrian University of Athens Athens Greece

Nicolaus Copernicus Hospital Toruń Poland

Onyx Pharmaceuticals Inc an Amgen subsidiary South San Francisco CA USA

Petz Aladár Megyei Oktató Kórház Vasvári Pál Hungary

Sapienza University of Rome Rome Italy

Southampton General Hospital Hampshire UK

St István and St László Hospital of Budapest Budapest Hungary

University College London Cancer Institute London UK

University Hospital La Fe and Universidad Católica de València 'San Vicente Mártir' València Spain

University Hospital Olomouc and Medical Faculty of Palacky University Olomouc Olomouc Czech Republic

University Hospital Ostrava and Faculty of Medicine University of Ostrava Ostrava Czech Republic

University Medicine Mainz Mainz Germany

University of Pécs Pécs Hungary

University of Torino Torino Italy

Wilhelminen Cancer Research Institute Vienna Austria

Zamojski Szpital Niepubliczny Zamosc Poland

000: 00000naa a2200000 a 4500

001: bmc17031586

003: CZ-PrNML

005: 20171025115536.0

007: ta

008: 171025s2017 enk f 000 0|eng||

009: AR

024 7_: $a 10.1038/leu.2016.176 $2 doi

035 __: $a (PubMed)27416912

040 __: $a ABA008 $b cze $d ABA008 $e AACR2

041 0_: $a eng

044 __: $a enk

100 1_: $a Hájek, R $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

245 12: $a A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS) / $c R. Hájek, T. Masszi, MT. Petrucci, A. Palumbo, L. Rosiñol, A. Nagler, KL. Yong, A. Oriol, J. Minarik, L. Pour, MA. Dimopoulos, V. Maisnar, D. Rossi, H. Kasparu, J. Van Droogenbroeck, DB. Yehuda, I. Hardan, M. Jenner, M. Calbecka, M. Dávid, J. de la Rubia, J. Drach, Z. Gasztonyi, S. Górnik, X. Leleu, M. Munder, M. Offidani, N. Zojer, K. Rajangam, YL. Chang, JF. San-Miguel, H. Ludwig,

520 9_: $a This randomized, phase III, open-label, multicenter study compared carfilzomib monotherapy against low-dose corticosteroids and optional cyclophosphamide in relapsed and refractory multiple myeloma (RRMM). Relapsed and refractory multiple myeloma patients were randomized (1:1) to receive carfilzomib (10-min intravenous infusion; 20 mg/m(2) on days 1 and 2 of cycle 1; 27 mg/m(2) thereafter) or a control regimen of low-dose corticosteroids (84 mg of dexamethasone or equivalent corticosteroid) with optional cyclophosphamide (1400 mg) for 28-day cycles. The primary endpoint was overall survival (OS). Three-hundred and fifteen patients were randomized to carfilzomib (n=157) or control (n=158). Both groups had a median of five prior regimens. In the control group, 95% of patients received cyclophosphamide. Median OS was 10.2 (95% confidence interval (CI) 8.4-14.4) vs 10.0 months (95% CI 7.7-12.0) with carfilzomib vs control (hazard ratio=0.975; 95% CI 0.760-1.249; P=0.4172). Progression-free survival was similar between groups; overall response rate was higher with carfilzomib (19.1 vs 11.4%). The most common grade ⩾3 adverse events were anemia (25.5 vs 30.7%), thrombocytopenia (24.2 vs 22.2%) and neutropenia (7.6 vs 12.4%) with carfilzomib vs control. Median OS for single-agent carfilzomib was similar to that for an active doublet control regimen in heavily pretreated RRMM patients.

650 _2: $a hormony kůry nadledvin $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000305

650 _2: $a dospělí $7 D000328

650 _2: $a senioři $7 D000368

650 _2: $a senioři nad 80 let $7 D000369

650 _2: $a anemie $x chemicky indukované $7 D000740

650 _2: $a cyklofosfamid $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D003520

650 _2: $a přežití po terapii bez příznaků nemoci $7 D018572

650 _2: $a ženské pohlaví $7 D005260

650 _2: $a lidé $7 D006801

650 _2: $a mužské pohlaví $7 D008297

650 _2: $a lidé středního věku $7 D008875

650 _2: $a mnohočetný myelom $x komplikace $x farmakoterapie $x mortalita $7 D009101

650 _2: $a neutropenie $x chemicky indukované $7 D009503

650 _2: $a oligopeptidy $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D009842

650 _2: $a recidiva $7 D012008

650 _2: $a záchranná terapie $x škodlivé účinky $x metody $x mortalita $7 D016879

650 _2: $a míra přežití $7 D015996

650 _2: $a trombocytopenie $x chemicky indukované $7 D013921

655 _2: $a klinické zkoušky, fáze III $7 D017428

655 _2: $a časopisecké články $7 D016428

655 _2: $a multicentrická studie $7 D016448

655 _2: $a randomizované kontrolované studie $7 D016449

700 1_: $a Masszi, T $u St István and St László Hospital of Budapest, Budapest, Hungary.

700 1_: $a Petrucci, M T $u Sapienza University of Rome, Rome, Italy.

700 1_: $a Palumbo, A $u University of Torino, Torino, Italy.

700 1_: $a Rosiñol, L $u Hospital Clínic de Barcelona, Barcelona, Spain.

700 1_: $a Nagler, A $u Chaim Sheba Medical Center, Tel Hashomer, Israel.

700 1_: $a Yong, K L $u University College London Cancer Institute, London, UK.

700 1_: $a Oriol, A $u Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Barcelona, Spain.

700 1_: $a Minarik, J $u University Hospital Olomouc and Medical Faculty of Palacky, University Olomouc, Olomouc, Czech Republic.

700 1_: $a Pour, L $u University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.

700 1_: $a Dimopoulos, M A $u National and Kapodistrian University of Athens, Athens, Greece.

700 1_: $a Maisnar, V $u Charles University Teaching Hospital, Hradec Králové, Czech Republic.

700 1_: $a Rossi, D $u Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.

700 1_: $a Kasparu, H $u Hospital Elisabethinen Linz, Linz, Austria.

700 1_: $a Van Droogenbroeck, J $u AZ Sint-Jan, Brugge, Belgium.

700 1_: $a Yehuda, D B $u Hadassah Medical Center, Jerusalem, Israel.

700 1_: $a Hardan, I $u Meir Medical Center, Kfar-Saba, Israel.

700 1_: $a Jenner, M $u Southampton General Hospital, Hampshire, UK.

700 1_: $a Calbecka, M $u Nicolaus Copernicus Hospital, Toruń, Poland.

700 1_: $a Dávid, M $u University of Pécs, Pécs, Hungary.

700 1_: $a de la Rubia, J $u University Hospital La Fe and Universidad Católica de València 'San Vicente Mártir', València, Spain.

700 1_: $a Drach, J $u Medical University of Vienna, Vienna, Austria.

700 1_: $a Gasztonyi, Z $u Petz Aladár Megyei Oktató Kórház, Vasvári Pál, Hungary.

700 1_: $a Górnik, S $u Zamojski Szpital Niepubliczny, Zamosc, Poland.

700 1_: $a Leleu, X $u Hopital Huriez, CHRU, Lille, France.

700 1_: $a Munder, M $u University Medicine Mainz, Mainz, Germany.

700 1_: $a Offidani, M $u Clinica di Ematologia Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, Ancona, Italy.

700 1_: $a Zojer, N $u Center for Oncology, Hematology with Outpatient Department and Palliative Care, Wilhelminenspital, Vienna, Austria.

700 1_: $a Rajangam, K $u Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.

700 1_: $a Chang, Y-L $u Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, CA, USA.

700 1_: $a San-Miguel, J F $u Clínica Universidad de Navarra-CIMA-IDISNA, Navarra, Spain.

700 1_: $a Ludwig, H $u Wilhelminen Cancer Research Institute, Vienna, Austria.

773 0_: $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 31, č. 1 (2017), s. 107-114

856 41: $u https://pubmed.ncbi.nlm.nih.gov/27416912 $y Pubmed

910 __: $a ABA008 $b sig $c sign $y a $z 0

990 __: $a 20171025 $b ABA008

991 __: $a 20171025115618 $b ABA008

999 __: $a ok $b bmc $g 1255179 $s 992613

BAS __: $a 3

BAS __: $a PreBMC

BMC __: $a 2017 $b 31 $c 1 $d 107-114 $e 20160624 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138

LZP __: $a Pubmed-20171025

Najít záznam

v PubMed

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Najít záznam

Citační ukazatele

Možnosti archivace